['The aim of this study was to assess the association between human fibroblast growth factor receptor 4 (FGFR4) Gly(388) Arg polymorphism and pre-eclampsia (PE) by carrying out a case-control study in Turkish women.', 'In the present study 159 PE patients and 161 controls were included. DNA was extracted from peripheral blood leukocyte and FGFR4 Gly(388) Arg polymorphism was investigated using polymerase chain reaction-restriction fragment length polymorphism methods.', 'For Gly388Arg polymorphism of FGFR4 we found no significant association between controls and PE patients. The frequencies of GlyGly, GlyArg and ArgArg genotypes were 56.6%, 36.4% and 7% for the study group and 50.3%, 44.7% and 5% for the control group, respectively. The risk of women with the GlyArg (odds ratio = 0.7, 95% confidence interval: 0.45-1.14) and ArgArg (odds ratio = 1.2, 95% confidence interval: 0.47-3.22) genotypes for PE did not differ significantly from that of GlyGly genotype carriers.'] Is fibroblast growth factor receptor 4 Gly388 Arg polymorphism associated with pre-eclampsia in Turkish women?